SIROLIMUS VS STANDARD TREATMENT IN HIGH RISK PEDIATRIC RENAL TRANSPLANT

本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。确定在接受西罗莫司或标准治疗36个月后，活检证实的排斥反应、移植物丢失或死亡的联合终点和复合终点是否存在差异。测定移植物内、循环血液和尿液中细胞因子谱的变化，以及经皮肾活检中纤维化表面积的变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Determine whether there is a difference in the combined and the composite endpoint of biopsy proven rejection, graft loss or death after 36 months of treatment with Sirolimus or standard treatment. Determine change in cytokine profile intra-graft, in circulating blood and in urine, and change in the fibrosis surface area in percutaneous renal biopsies.